Advanced search

Thanks to the West Bridge program, Ukrainian businesses continue to develop in EU countries. Another of the program’s significant projects is financing a new pharmaceutical plant for the largest Ukrainian drug manufacturer, Farmak, in Spain. This joint effort by the Pivdenny Bank and the Latvian bank Regionala Investiciju Banka has provided the Farmak group with a €12M loan. With this, Farmak continues implementing its corporate development strategy, Farmak 2.0: from local to global success. The company’s new Spanish project is

Ukrainian Pharmaceutical company Farmak is investing over €20M to construct a new plant in Spain. The new facility will be built in the suburbs of Barcelona and will start operating in early 2024, according to the company’s press service. The enterprise, with a complete supply chain, a closed production cycle, and quality control, will produce sterile medicinal products in the form of solutions, suspensions in vials, and syringes. According to the company, the production of medicine will comply with European

 The EBRD is lending €20M to a leading Ukrainian pharmaceuticals manufacturer under its €2B Resilience and Livelihoods Framework, supporting countries affected by the war in Ukraine. The financing, which will provide working capital to a manufacturer with a 5.7 % pre-war share of Ukraine’s pharmaceuticals market, will support production and improve access to essential medicines for people living in Ukraine. Supporting the pharmaceutical sector during the war in Ukraine is a crucial element of the bank’s five-pronged support plan for

According to Farmak director Volodymyr Kostyuk, the company started investing in the venture capital market in 2020. The company is interested in advanced rapid diagnostics, digital medicine, and interactive patient involvement, which diagnoses and predicts possible health problems. After analyzing the venture capital market in Ukraine and abroad, Farmak selected several more startups for investments. One of the investments is in American biotech startup Cambrian Biopharma, which is developing innovative drugs to combat the biological factors of aging, treat and

The leading pharmaceutical manufacturer and exporter of medicines, has opened a representative office in Vietnam. The company has been active in the Vietnamese market since 2007, when it sold 25 of its products through local distributors.

, the company said in a press release. “By supporting such projects, we are contributing to the achievement of the Global Sustainable Development Goals, one of the tasks of which is to improve the quality of higher education and ensure its close connection with science,” said Volodymyr Kostyuk, Executive Director of Farmak.